A Phase II Trial of Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma (BMS #CA225-331/Lilly Trial Alias I4E-US-X007)

Trial Profile

A Phase II Trial of Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma (BMS #CA225-331/Lilly Trial Alias I4E-US-X007)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Apr 2017

At a glance

  • Drugs Cetuximab (Primary) ; Cisplatin; Cyclophosphamide; Doxorubicin
  • Indications Malignant thymoma; Thymoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Apr 2017 Planned number of patients changed from 28 to 18.
    • 04 Apr 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
    • 04 Apr 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top